Text alternative
- Was the infant born or after 1 January 2025?
- If no, the infant is not eligible for nirsevimab1
- If yes, was the maternal RSV vaccine (Abrysvo) received <2 weeks before birth?2
- If yes, provide nirsevimab at birth5.
- If no, was infant born with risk conditions3 for severe RSV disease regardless of maternal vaccination status.
- If yes, provide nirsevimab at birth5.
- If no, was mother with severe immunosuppression4 or undergone cardiopulmonary bypass or extracorporeal membrane oxygenation (ECMO) regardless of maternal vaccination status?
- If yes, provide nirsevimab at birth5.
- If no, nirsevimab not required.
References
-
Refer to the
Clinical decision aid for nirsevimab (Beyfortus™) in infants and children up to 24 months of age who remain at risk of severe RSV disease.
-
Check maternal RSV vaccination status on the Australian Immunisation Register
-
Conditions associated with increased risk of severe RSV disease in infants and young children as
recommended in the Australian Immunisation Handbook include:
- preterm birth <32 weeks gestational age
- ongoing haemodynamically significant congenital heart disease
- significant immunosuppression, such as from solid organ transplant, haematopoietic stem cell
transplant, or primary immune deficiencies such as severe combined immunodeficiency (SCID) in
consultation with a paediatric infectious disease, immunology or
immunisation specialist. - chronic lung disease requiring ongoing oxygen or respiratory support
- neurological conditions that impair respiratory function
- cystic fibrosis with severe lung disease or weight for length <10th percentile
- trisomy 21 or another genetic condition that increases the risk of
severe RSV disease
-
Refer to the Australian Immunisation Handbook Vaccination for people who are immunocompromised chapter
-
The dose of nirsevimab for infants weighing <5 kg, born during or entering their 1st RSV season, is 50 mg (0.5 mL). The dose of nirsevimab for infants weighing ≥5 kg, born during or entering their 1st RSV season, is 100 mg (1 mL). Nirsevimab is administered by intramuscular injection.
Note:
Newborn infants should receive nirsevimab prior to discharge from hospital. Primary care providers with an eligible newborn infant born on or after 1 January 2025 who did not receive nirsevimab before discharge from hospital must use the nirsevimab order form on the NSW State Vaccine Centre to order nirsevimab for each eligible infant.